Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis

BACKGROUND/AIMS: The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, depending on their CYP3A5 expression status. Here, we ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Okabayashi, Shinji, Kobayashi, Taku, Saito, Eiko, Toyonaga, Takahiko, Ozaki, Ryo, Sagami, Shintaro, Nakano, Masaru, Tanaka, Junichi, Yagisawa, Keiji, Kuronuma, Satoshi, Takeuchi, Osamu, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505090/
https://www.ncbi.nlm.nih.gov/pubmed/30704156
http://dx.doi.org/10.5217/ir.2018.00117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505090/
https://www.ncbi.nlm.nih.gov/pubmed/30704156
http://dx.doi.org/10.5217/ir.2018.00117

Ejemplares similares